Seeking Alpha1mon
Bayer: Sell And Be Done With It
Meanwhile, Bayer's Pharmaceutical division has delivered ... This growth was driven by significant gains from new products, with Nubeqa and Kerendia achieving growth rates of 83.2% and 96.4% ...
Hosted on MSN26d
Bayer attacked bureaucracy by firing some 5,000 managers and asking teams to ‘self-organize.’ Here’s how it’s going after one year
So I was intrigued to read last year about the radical plan to attack bureaucracy at German pharma company Bayer. The company ... and our products.” But little changes, he ventured, would ...
FiercePharma16d
JPM25: Bayer gears up for 'must-win battles' as Xarelto's decline is in full swing, pharma chief says
The optimism is rooted in new launches, Stefan Oelrich, head of Bayer’s pharma division, said Tuesday at the J.P. Morgan Healthcare Conference. Besides label expansions for in-market products ...
FiercePharma1d
Eylea-Vabysmo battle wages on as UK marketing watchdog reaffirms Bayer’s claims of ‘misleading’ Roche promos
The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...
Yahoo Finance18d
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
Bayer recently submitted an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for this third indication for darolutamide in addition ...
Forbes24d
Cutting Middle Management: Bayer's Costly Experiment One Year Later
In a bold move to restore $540 million in cost savings, Bayer CEO Bill Anderson cut out ... teams with a clearer focused on our customers and products,” Hayes shares. Anderson’s push for ...
Wall Street Journal18d
Bayer’s Head of Pharma Oelrich Expects Business to Return to Growth in 2027
Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...
Reuters16d
Bayer AG
Bayer pharma chief sees no big acquisitions in near ... and potentially the rise of novel legal theories applied to less traditional products. Here are some of the top cases to watch in 2025.
Bayer AG Enterprise Digital Transformation Strategy Report 2024: Accelerators, Incubators, and Innovation Programs
The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into Bayer AG's tech activities, including its digital ...
Business Wire22d
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
As a true life-science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence – from innovative products to high-quality services – to support ...
Yahoo Finance18d
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
At the same time, the value of our pipeline is growing by accelerating breakthrough innovations," said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s ...